{
  "abstract": "B7-H3 (CD276) is broadly overexpressed across solid tumors and plays active roles in immune evasion, tumor angiogenesis, and metabolic reprogramming. As B7-H3-directed antibody-drug conjugates chimeric antigen receptor T-cell therapies, and radioimmunotherapy agents advance through clinical trials, non-invasive whole-body imaging of B7-H3 expression has become a pressing clinical need. Tissue biopsy with IHC cannot capture systemic target heterogeneity, and the recent IDeate-PanTumor01 trial found no correlation between baseline B7-H3 H-score and response to ifinatamab deruxtecan-illustrating the gap that molecular imaging must fill. This mini review surveys B7-H3-targeted imaging agents by scaffold class-antibodies, affibodies, nanobodies, and bicyclic peptides-and examines radioimmunotherapy platforms that couple PET-based dosimetry with targeted radionuclide delivery.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Occupational Pulmonology, Shandong First Medical University Affiliated Occupational Disease Hospital (Shandong Occupational Disease Hospital), Jinan, Shandong, China.",
    "Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China."
  ],
  "article_type": "review article",
  "arxiv": null,
  "author_total": 4,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Baoyan Liu"
    },
    {
      "affs": [
        1
      ],
      "name": "Kelin Wang"
    },
    {
      "affs": [
        1
      ],
      "name": "Kewen He"
    },
    {
      "affs": [
        1
      ],
      "name": "Yong Wang"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/7433zp3y26558.bib",
  "cited_by": 0,
  "doi": "10.3389/fphar.2026.1923470",
  "fulltext_url": "https://europepmc.org/articles/PMC13680445",
  "id": "7433zp3y26558",
  "issns": [
    "1663-9812"
  ],
  "landing_url": "https://europepmc.org/article/MED/42903186",
  "language": "eng",
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2741|Radiopharmaceutical Chemistry and Applications"
    ]
  ],
  "openalex": "W7220738992",
  "pdf_url": "https://europepmc.org/articles/PMC13680445?pdf=render",
  "pmcid": "PMC13680445",
  "pmid": "42903186",
  "published": "2026-10-06",
  "publisher": "Frontiers Media SA",
  "ris": "https://research.draconitic.com/paper/7433zp3y26558.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:19:57Z",
      "native_id": "MED:42903186",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42903186"
    },
    {
      "first_seen": "2026-10-30T12:20:06Z",
      "native_id": "10.3389/fphar.2026.1923470",
      "source": "crossref",
      "url": "https://www.frontiersin.org/articles/10.3389/fphar.2026.1923470/full"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2741|Radiopharmaceutical Chemistry and Applications",
      "subfield": "imaging"
    }
  ],
  "title": "B7-H3 molecular imaging for the era of pan-cancer targeted therapy.",
  "title_text": "B7-H3 molecular imaging for the era of pan-cancer targeted therapy.",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:20:06Z",
  "url": "https://research.draconitic.com/paper/7433zp3y26558",
  "venue": "Frontiers in pharmacology",
  "versions": []
}